Analysts expect Kadmon Co. (NYSE:KDMN) to report earnings per share (EPS) of ($0.25) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Kadmon’s earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.23). Kadmon reported earnings per share of ($0.39) in the same quarter last year, which would indicate a positive year-over-year growth rate of 35.9%. The business is expected to report its next quarterly earnings results on Monday, May 21st.
According to Zacks, analysts expect that Kadmon will report full-year earnings of ($1.11) per share for the current year, with EPS estimates ranging from ($1.25) to ($0.96). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.91) per share, with EPS estimates ranging from ($1.29) to ($0.38). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Kadmon.
Kadmon (NYSE:KDMN) last released its earnings results on Tuesday, March 6th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.12. The firm had revenue of $1.50 million for the quarter, compared to the consensus estimate of $3.07 million. During the same period in the prior year, the business earned ($0.50) EPS. The company’s quarterly revenue was down 65.1% on a year-over-year basis.
NYSE:KDMN opened at $3.98 on Friday. Kadmon has a 52 week low of $2.05 and a 52 week high of $5.86.
Several institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN raised its position in shares of Kadmon by 23.2% during the 3rd quarter. Wells Fargo & Company MN now owns 73,956 shares of the company’s stock worth $247,000 after purchasing an additional 13,923 shares during the period. Bank of New York Mellon Corp raised its position in shares of Kadmon by 66.6% during the 4th quarter. Bank of New York Mellon Corp now owns 59,430 shares of the company’s stock worth $216,000 after purchasing an additional 23,763 shares during the period. BlueCrest Capital Management Ltd acquired a new stake in shares of Kadmon during the 4th quarter worth approximately $241,000. BlackRock Inc. raised its position in shares of Kadmon by 151.2% during the 4th quarter. BlackRock Inc. now owns 208,190 shares of the company’s stock worth $754,000 after purchasing an additional 125,308 shares during the period. Finally, AE Wealth Management LLC raised its position in shares of Kadmon by 61.1% during the 4th quarter. AE Wealth Management LLC now owns 520,713 shares of the company’s stock worth $1,885,000 after purchasing an additional 197,552 shares during the period. Institutional investors and hedge funds own 61.71% of the company’s stock.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.